Stock Research: NovoCure

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

NovoCure

NSQ:NVCR JE00BYSS4X48
7
  • Value
    29
  • Growth
    30
  • Safety
    Safety
    34
  • Combined
    10
  • Sentiment
    27
  • 360° View
    360° View
    7
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

NovoCure Limited is a global oncology company developing Tumor Treating Fields (TTFields) devices. The company operates in the medical device industry. It operates globally, with a license to market Optune in China, Hong Kong, Macau, and Taiwan. In the last fiscal year, the company had a market cap of $1,887 million, profits of $468 million, and revenue of $605 million, with 1488 employees.

more
Index
NASDAQ
D.J. US Medical Equipment
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Feb-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
29 20 27 11
Growth
30 80 19 55
Safety
Safety
34 7 25 12
Sentiment
27 30 1 10
360° View
360° View
7 9 1 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
61 51 28 3
Opinions Change
12 40 9 26
Pro Holdings
n/a 23 6 72
Market Pulse
76 63 12 38
Sentiment
27 30 1 10
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
29 20 27 11
Growth
30 80 19 55
Safety Safety
34 7 25 12
Combined
10 17 6 6
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
50 27 46 3
Price vs. Earnings (P/E)
4 4 4 4
Price vs. Book (P/B)
25 11 28 12
Dividend Yield
1 1 1 1
Value
29 20 27 11
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
21 1 33 52
Profit Growth
36 74 6 52
Capital Growth
96 100 98 90
Stock Returns
9 84 3 7
Growth
30 80 19 55
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
17 1 6 12
Refinancing
82 62 93 67
Liquidity
14 7 8 4
Safety Safety
34 7 25 12

Similar Stocks

Discover high‑ranked alternatives to NovoCure and broaden your portfolio horizons.

STMicroelectronics

PAR:STMPA
Country: Netherlands
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

KSB

GER:KSB
Country: Germany
Industry: Industrial Machinery
Size: Medium
Full Stock Analysis

Betsson

STO:BETS B
Country: Sweden
Industry: Casinos & Gaming
Size: Medium
Full Stock Analysis

L.D.C.

PAR:LOUP
Country: France
Industry: Packaged Foods & Meats
Size: Large
Full Stock Analysis

Frequently Asked
Questions

This is a highly risky stock investment proposition as all consolidated ranks are below-average. There are no compelling arguments to support this stock based on current information. It is not recommended for any investor profile. However, performance does change, so it could we worth keepin on a watchlist.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: